OTC: CLVLY - Clinuvel Pharmaceuticals Limited

Yield per half year: -29.23%
Dividend yield: +0.35%
Sector: Healthcare

Share chart Clinuvel Pharmaceuticals Limited

Extended chart Simple chart
Financial Markets by TradingView

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

more details
The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

ISIN US1887691038
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0.3469
Дивиденд ао 0.034
Сайт https://www.clinuvel.com
Цена ао 7.63
Change price per day: 0% (6.9)
Change price per week: +7.41% (6.424)
Change price per month: -5.48% (7.3)
Change price per 3 month: -5.22% (7.28)
Change price per half year: -29.23% (9.75)
Change price per year: -29.23% (9.75)
Change price per 3 year: -47.91% (13.2465)
Change price per 5 year: -60.77% (17.59)
Change price per year to date: -9.92% (7.66)
All parameters

Underestimation

Title Value Grade
P/S 5.76 2
P/BV 2.5 6
P/E 14.26 8
EV/EBITDA 5.78 9
Total: 7.13

Efficiency

Title Value Grade
ROA, % 19.75 6
ROE, % 22.79 7
Total: 7.83

Dividends

Title Value Grade
Div yield, % 0.3469 0.88
DSI 1 10
Total: 3.84

Debt

Title Value Grade
Debt/EBITDA 0.0156 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 170.49 10
Yield Ebitda, % 313.79 10
Yield EPS, % 111.63 10
Total: 9.4
More

Institutions Volume Share, %
Trust For Professional Managers-PMC Diversified Equity Fund 4782 0.01



Head Job title Payment Year of birth
Dr. Philippe Jacques Wolgen M.B.A., M.D. CEO, MD & Director 1.86M 1963 (62 years)
Mr. Lachlan Hay Chief Operations Officer N/A
Mr. Malcolm Bull Head of Australian Operations & Investor Relations N/A
Dr. Rose Quadbeck-Diel Senior Vice President of Regulatory Affairs N/A
Dr. Azza Hamila Head of Quality Assurance & Drug Safety N/A
Dr. Dennis J. Wright BPharm, M.Sc., Ph.D. Chief Scientific Officer
Mr. Peter Vaughan Chief Financial Officer
Ms. Claire Newstead-Sinclair C.A. Company Secretary

Address: Australia, Melbourne. VIC, 535 Bourke Street - open in Google maps, open in Yandex maps
Website: https://www.clinuvel.com